12% of the Irish population is believed to be suffering from
depression, whilst 800,000 deaths are reported annually
worldwide. Depression will, therefore, be the largest contributor
to disease burden by 2030 and there is an urgent need to develop
improved treatments. Current pharmacotherapies are based upon
the monoamine theory of depression. Conventional
antidepressants can induce unpleasant side-effects, resulting in low
patient compliance and a high failure response rate.